i3 Research Acquires SKM Oncology
Creates Leadership Position in Oncology
BASKING RIDGE, NJ, June 20, 2005 - i3 Research, a global contract research organization (CRO) providing clinical trial services specialized in oncology, central nervous system, respiratory and infectious disease, has acquired SKM Oncology and its related businesses. SKM is a full-service CRO and a leader in the delivery of oncology clinical trials in Germany. Its coverage and strength in the key German marketplace, coupled with i3's therapeutic specialization and geographic reach, elevate i3 to a global leadership position in the oncology product development marketplace.
"The SKM acquisition fits perfectly into our specialization strategy to focus on a limited number of key therapeutic areas in which we know we can provide unparalleled quality clinical research services, rather than trying to become experts in every area," said Nigel Page, i3 Research president. "In addition to supplementing our capabilities in the oncology area, SKM provides us with a solid delivery platform for our services in the German market, and to Europe beyond."
Founded in 1996, SKM has four offices in Germany and one in Vienna, Austria. "The combined i3-SKM organization will provide our customers with exceptional access to oncology thought leaders and patients, and great experience in oncology trial delivery," said Renate Walter-Kirst, SKM founder and CEO. "It illustrates the investment and commitment i3 is making to bring ever-greater expertise, capabilities and value to its customers."
About i3
i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It comprises: i3 Research, a therapeutically specialized contract research organization; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; i3 Magnifi, delivering the science and solutions to achieve marketplace success; and i3 DLN, providing continuing medical education. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
